Overview

Basic information

Litigation

Active legal matters

Material Events

8-K disclosures

SEC Filings

Key regulatory docs

Insider Transactions

Ownership changes

Overview

Basic information

Litigation

Active legal matters

Material Events

8-K disclosures

SEC Filings

Key regulatory docs

Insider Transactions

Ownership changes

Lipocine Inc. (LPCN) Class Action Lawsuit (November 2019)

Closed

2:19cv906 • November 14, 2019

Class Period Start

January 28, 2019

Class Period End

November 11, 2019

PSLRA Deadline

January 14, 2020

Case Allegations

10b5

Statutes of Repose

Jan 28, 2022

Country

United States

Court

Federal Court

Docket History

May 13, 2023

No Appeal- Closed

Apr 13, 2023

Motion to Dismiss Granted

The court has granted the defendants' request to dismiss the lawsuit. Depending on the court's decision, the plaintiffs may be allowed to file an updated complaint or pursue an appeal.

Jul 24, 2020

Motion to Dismiss

After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.

May 26, 2020

First Amended Complaint

A new complaint has been filed on behalf of certain investors in Lipocine Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

Apr 10, 2020

Scheduling Order

Feb 24, 2020

Appointment of Lead Plaintiff

The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.

Nov 14, 2019

First Filed Complaint

A securities fraud class action complaint has been filed on behalf of certain investors in Lipocine Inc..

TOP